Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cholecalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholecalciferol SCHEMBL12358252 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL10034116 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL7151131 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL15694 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL3127 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL23878716 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL8030832 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL21264875 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL20511118 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL267918 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021128-A1 | COMPOSITION INCLUDING POLYENE ANTIFUNGAL DRUG AND USE THEREOF | UNIV JINAN (CN) | 2026-01-22 | — | — | US | claimed |
| EP-4507685-A1 | CELL DIFFERENTIATION | John Hemming Trading Ltd (GB) | 2025-02-19 | — | — | EP | claimed |
| US-20240382567-A1 | Long-acting PTH compound treatments | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-11-21 | — | — | US | claimed |
| WO-2024198496-A1 | POLYENE ANTIFUNGAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | 暨南大学 | 2024-10-03 | — | — | WO | claimed |
| EP-4404951-A1 | LONG-ACTING PTH COMPOUND TREATMENTS | Ascendis Pharma Bone Diseases A/S (DK) | 2024-07-31 | — | — | EP | claimed |
| US-20240122851-A1 | VITAMIN D FORMULATIONS | Solmic Biotech GmbH (DE) | 2024-04-18 | — | — | US | claimed |
| US-11911398-B2 | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | OPKO RENAL, LLC (US) | 2024-02-27 | — | — | US | claimed |
| EP-4312985-A1 | VITAMIN D FORMULATIONS | Solmic Biotech GmbH (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2023199024-A1 | CELL DIFFERENTIATION | JOHN HEMMING TRADING LTD (GB) | 2023-10-19 | — | — | WO | claimed |
| US-20230248744-A1 | 25-HYDROXYVITAMIN D2 AND/OR D3 FOR USE IN OBESITY | CARBOGEN AMCIS B.V. (NL) | 2023-08-10 | — | — | US | claimed |
| WO-2022195016-A1 | VITAMIN D FORMULATIONS | Solmic Biotech GmbH (DE) | 2022-09-22 | — | — | WO | claimed |
| US-11435367-B2 | Methods and kits for assaying a vitamin D moiety | DIAZYME LABORATORIES, INC. (US) | 2022-09-06 | — | — | US | claimed |
| WO-2022145511-A1 | METHOD FOR PROVIDING INFORMATION FOR PREDICTING DIABETIC CATARACT | 경상국립대학교병원 | 2022-07-07 | — | — | WO | claimed |
| US-20220142166-A1 | ATTRACTANTS FOR RODENTS | GRIES, GERHARD (CA) | 2022-05-12 | — | — | US | claimed |
| US-11185077-B2 | Attractants for rodents | GRIES GERHARD (CA) | 2021-11-30 | — | — | US | claimed |
| US-20190335740-A1 | ATTRACTANTS FOR MICE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-11-07 | — | — | US | claimed |
| US-20190183126-A1 | ATTRACTANTS FOR RODENTS | GRIES GERHARD (CA) | 2019-06-20 | — | — | US | claimed |
| US-20190110475-A1 | ATTRACTANTS FOR MICE | GERHARD GRIES (CA) | 2019-04-18 | — | — | US | claimed |
| US-20180352802-A1 | ATTRACTANTS FOR RATS | GRIES GERHARD (CA) | 2018-12-13 | — | — | US | claimed |
| US-20140200201-A1 | Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021128-A1 | COMPOSITION INCLUDING POLYENE ANTIFUNGAL DRUG AND USE THEREOF | VDR, CYP24A1, CFD | VDR 1/4885MEN1 482/4885KMT2A 4536/4885 |
| US-20240122851-A1 | VITAMIN D FORMULATIONS | VDR, CYP24A1, CYP27B1 | VDR 1/4885MEN1 880/4885KMT2A 3875/4885 |
| US-20240382567-A1 | Long-acting PTH compound treatments | PTH1R, SOST, CALCA | VDR 12/4885MEN1 90/4885KMT2A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.